Catalysts Ahead: Small-Cap Stocks to Watch for Breakouts (STSS, GNLN, KAVL, NKGN. REVB)

Uncovering the hidden potential of small-cap stocks can result in substantial profits for investors. These often-overlooked companies capitalize on a variety of catalysts that contribute to their success. In this article, we highlight five small-cap stocks, examining the elements that are driving their growth and sparking investor interest.

Sharps Technology Inc. (NASDAQ: STSS) - Sharps Technology Inc. shares closed last week’s trading session up 16% at $2.89. In July, the company finalized a major contract with a leading U.S.-based supplier of medical saline and water products to provide customized 10mL SoloGard syringes from its EU manufacturing facility. This partnership emerged as the customer evaluated Sharps' SoloGard syringes in response to recent FDA recalls and tariffs on Chinese-made syringes. Following a successful evaluation, the two companies signed a five-year sales agreement, fully utilizing Sharps’ current manufacturing capacity for the 10mL SoloGard product. This strategic syringe program will require immediate expansion to support additional customer projects at the company’s Hungary plant. Robert Hayes, CEO of Sharps Technology, remarked, “Establishing this partnership and selling out the Hungary plant's production capacity for the next five years is a historic milestone for Sharps. This collaboration creates a five-year agreement for at least 500 million syringes, consuming the available manufacturing capacity for our 10mL SoloGard syringes. It also provides a clear path to near-term revenue starting in Q4 2024, with a gradual ramp-up into 2025.” In August, Sharps confirmed in a regulatory filing that on July 24, 2024, it entered into a Supply Agreement with Stericare Solutions, LLC, a Texas-based company. Under this agreement, Stericare will purchase 520 million 10mL polypropylene SoloGard syringes. While the specific pricing remains confidential, the company expects total revenues to exceed $50 million. The agreement outlines the following delivery schedule: 40 million units in the first year, followed by 120 million units annually for the remainder of the five-year term, which is set to begin on November 1, 2024. As we await further developments, we are watching key levels—specifically, a resistance break between $3.00 and $3.05 or sustained support around $2.60.

--

Greenlane Holdings, Inc. (NASDAQ: GNLN) - Greenlane Holdings, Inc. shares closed last week’s trading session up 4% at $4.50. This month, the company announced it had entered into a non-binding letter of intent (LOI) to become a distributor for CURB Lifestyle, Inc.’s patented, non-heating inhalation device across the U.S., Canada, Latin America, and the EU. CURB’s device is designed to safely deliver various formulations, including nicotine, cannabinoids, and wellness compounds, and targets several multi-billion-dollar markets, primarily in nicotine, cannabis, and wellness sectors. The CURB products will be available to order starting November 15, 2024 through Greenlane’s online retail platforms—vapor.com, puffitup.com, and higherstandards.com—as well as its wholesale portal at wholesale.greenlane.com. Additionally, Greenlane plans to offer the device to its dispensary clients as a healthier alternative for cannabis consumption. “CURB has established a new standard in inhalation devices, delivering a safer, more convenient, and consistent system for consumers—whether they’re seeking recreational enjoyment or wellness support,” said Barbara Sher, Chief Executive Officer of Greenlane. “As a leading global distributor of premium lifestyle products, the launch of the CURB device on our platform marks an exciting milestone at the start of our strategic collaboration.” Looking ahead, we will monitor for a resistance break at $4.65, ideally accompanied by increased trading volume. Additionally, it is worth noting that Greenlane’s S-1 filing became effective in September, signaling potential developments on the horizon.

--

Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) - Kaival Brands Innovations Group, Inc. shares closed last week’s session up 5%, ending at $0.89. Last month, Kaival, a Delaware-based corporation and the exclusive U.S. distributor of the Bidi® Stick and other products from Bidi Vapor, LLC, announced a key development with Delta Corp Holdings Limited. Delta, a UK-incorporated holding company involved in bulk and energy logistics, fuel supply, and asset management, joined Kaival in confidentially submitting a draft registration statement on Form F-4 with the U.S. Securities and Exchange Commission (SEC). This filing relates to a Merger and Share Exchange Agreement announced on September 23, 2024, under which Kaival and Delta will become wholly owned subsidiaries of a newly formed public holding company called Pubco, incorporated in the Cayman Islands. Following the merger, Pubco will serve as the new publicly listed parent company. According to a September filing, either Kaival or Delta can terminate the agreement under specific conditions, such as: If either party experiences a Material Adverse Effect that is unresolved. If shareholder approval of the merger agreement and related transactions is not obtained at a special meeting. If Kaival’s board changes its recommendation or accepts a takeover proposal. If Kaival does not provide executed voting agreements representing a majority of its outstanding common stock to Delta and Pubco by October 31, 2024. Weare closely monitoring the stock for any updates and are watching for a potential resistance break between $0.95 and $0.98, ideally supported by increased trading volume.

--

NKGen Biotech Inc. (NASDAQ: NKGN) - NKGen Biotech Inc. shares fell 42% last week, closing at $0.39. In September, the company reported encouraging early data from the Phase 1 cohort of its Phase 1/2a clinical trial for troculeucel, NKGen’s cryopreserved autologous enhanced NK cell therapy for moderate Alzheimer’s disease (AD). Interim results from the Phase 1 cohort are promising. An independent review showed that after three months of treatment, with each patient receiving 6 billion cells per dose, none experienced drug-related adverse reactions. Additionally, two of the three patients showed cognitive improvement, moving from moderate to mild AD on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale. These findings align with the company’s earlier MX04 Phase 1 AD study, where one patient receiving the highest dose (4 billion cells) also improved from moderate to mild AD on the same scale. The company expects to release six-month cognitive data from the Phase 1 cohort at an upcoming national Alzheimer’s conference in Q4 2024. This month, NKGen announced that it would present on troculeucel’s potential in treating neurodegenerative diseases and stroke at the 16th World Stroke Congress (WSC 2024), taking place in Abu Dhabi, UAE, from October 23–26, 2024. Although initially accepted as an oral presentation, the company will now present its findings in poster format. Additionally, NKGen will share two poster presentations—a final report from the Phase 1 dose escalation study and a preliminary report from the Phase 1 cohort of the Phase 1/2a trial—at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD), scheduled for October 29– November 1, 2024, in Madrid, Spain. Looking ahead, we are monitoring for a potential resistance break in the $0.46–$0.48 range. As previously disclosed, NKGen is addressing a Nasdaq delisting notice due to market capitalization deficiencies. On September 18, 2024, the company was notified that the delisting action, originally referenced in a September 10, 2024, deficiency letter, had been temporarily stayed pending a decision by a Nasdaq panel. The panel will review NKGen’s appeal at an oral hearing on October 31, 2024, where the company will present its plan to regain compliance with Nasdaq listing requirements.

--

Revelation Biosciences, Inc. (NASDAQ: REVB) - Revelation Biosciences, Inc. shares rose 8% last week, closing at $0.92. In September, the company announced statistically significant, dose-dependent increases in interleukin-10 (IL-10) in response to its Gemini treatment, confirmed through high-sensitivity analysis. This positive development builds on the topline data from the Phase 1 clinical study released on June 24, 2024. IL-10 is a potent anti-inflammatory protein that helps suppress pro-inflammatory cytokines, playing a crucial role in reducing inflammation. The increase in IL-10 without corresponding rises in pro-inflammatory markers—such as IL-1β and TNF-α—validates Gemini’s unique TLR4 binding mechanism. These findings further demonstrate Gemini’s ability to reprogram the innate immune response, enabling it to resolve inflammation and promote healing. “We are thrilled to observe such a clear increase in IL-10 levels," said James Rolke, CEO of Revelation Biosciences. "This confirms our ability to use Gemini to fine-tune the innate immune system and accelerate healing through immunostimulatory preconditioning. The new data highlights the potential benefit of Gemini for patients, and we are eager to advance into our Phase 1b study in late 2024.” As we await further updates, we will be monitoring for a resistance break in the $0.96–$0.97 range, ideally supported by increased volume.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.